Every Form 4 that Redhill Biopharma Ltd. (RDHL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RDHL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RDHL filings page.
RedHill Biopharma Ltd. Chief Operating Officer Gilead Raday reported acquiring 27,560,000 American Depository Shares through a derivative conversion on October 1, 2026; 131,690,000 American Depository Shares were reported following that entry. On the same date, a trustee sold 1,431 ADS, representing 14,310,000 ordinary shares, at $0.465 per ADS ($0.0000465 per ordinary share) to satisfy tax withholding on vesting of 4,187 RSUs. The sale was under a sell-to-cover policy and was not a discretionary trade by Raday; 176,910,000 ordinary shares were reported following the sale.
RedHill Biopharma Ltd. insider Raday Gilead, Chief Operating Officer, reported compensation-related equity activity. A trustee sold 1,413 American Depositary Shares (ADS), each representing 10,000 ordinary shares, solely to satisfy tax withholding obligations arising from the vesting of 4,228 restricted share units granted between July 2023 and January 2026. The ADS were sold at $0.6973 per ADS, equivalent to $0.00006973 per ordinary share, under a sell-to-cover policy and the filing states this did not represent a discretionary trade by Gilead. The report also shows a derivative exercise/conversion related to ADS into ordinary shares, with Gilead continuing to hold a substantial direct position after these transactions.
RedHill Biopharma Ltd. Chief Operating Officer Gilead Raday reported compensation-related share activity tied to restricted share unit vesting. A trustee sold 1,574 American Depositary Shares (ADS) solely to cover tax withholding, at $0.8001 per ADS, equal to 15,740,000 ordinary shares based on 10,000 ordinary shares per ADS. Following this sale, Raday’s direct holdings in ordinary shares were 261,060,000. He also exercised derivative rights over 30,780,000 ADS representing 30,780,000 underlying ordinary shares, leaving 76,150,000 ADS directly held. Footnotes state the transaction was executed under a sell-to-cover policy and did not represent a discretionary trade by Raday.